• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Drug or device? FDA loses this argument for now

Drug or device? FDA loses this argument for now

December 9, 2019 By Nancy Crotti

Genus Medical Technologies says its barium sulfate product is a device. (Image from Genus Medical Technologies)

This article has been updated with comments from an attorney for Genus Medical Technologies.

A federal judge has temporarily blocked an attempt by the FDA to regulate a barium sulfate product ingested before imaging as a drug.

The decision counts as at least a partial win for Genus Medical Technologies (St. Louis), maker of the Vanilla SilQ line of contrast agents used to image structures or fluids within the body. Judge James Boasberg of U.S. District Court for the District of Columbia on Friday kicked the case back to the FDA for further administrative proceedings.

Genus has manufactured Vanilla SilQ since 2015 and sought regulation for it as a device because its barium sulfate component, whose opacity enables healthcare providers to visualize the gastrointestinal tract. Barium sulfate is an inert metal salt that does not chemically interact with human cells or tissue, as a drug does.

The FDA issued a warning letter to Genus following a 2017 inspection. Genus took the matter to the FDA’s Office of Combination Products, which ruled that the product should be regulated as a drug.  Genus then sued the FDA seeking to have Vanilla SilQ regulated as a device — a far less complicated and costly route than regulation as a drug.

The FDA argued that although the Vanilla SilQ products appeared to qualify as a device under the federal Food Drug and Cosmetic Act, they were also drugs and could be regulated accordingly. When a product meets the definition of both drug and device, the agency claimed it has discretion to decide into which category to place it.

Genus estimated the cost of seeking clearance to market its product as a device at $60,000, whereas seeking approval to market it as a drug could exceed $500,000, plus a continuing annual cost of more than $186,000, according to the court order dismissing the FDA’s motion for summary judgment.

Genus attorney Douglas Farquhar told MassDevice in an interview that he doubted the FDA would again try to regulate Vanilla SilQ as a drug.  The company will probably file a 510(k) application to have the product cleared by the agency, he said.

The judge’s decision in this case may have implications for other medical products, added Farquhar, of the Washington, D.C. law firm of Hyman, Phelps & McNamara.

“If there are other products that meet the definition of device that FDA is regulating as a drug, then people who are marketing those products should be able to use this decision to challenge that determination,” Farquhar said.

The FDA did not immediately comment on the judge’s decision.

 

 

 

Filed Under: Diagnostics, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Imaging, Legal News, Regulatory/Compliance Tagged With: FDA, Genus Medical Technologies

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy